Aveta Biomics
Bedford, US · Founded 2013 · Delaware corporation
Find your way into Aveta Biomics
Sign up to see every warm intro you have to Aveta Biomics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aveta Biomics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Aveta Biomics develops cancer therapeutics based on Orthologous Molecular Structures (OMS), metabolites from organisms with orthologous genes and processes, combined using an evolutionary-biology-based platform. Its drugs aim to treat and prevent cancers while addressing tumor heterogeneity and drug resistance.
Founders & leadership
PM

Parag MehtaCEOExecutive officer and director at Aveta Biomics, with background spanning business development, product development, manufacturing, and venture capital financing across advanced materials, imaging, clean technology, and biotechnology sectors.
SM
Sharmila MudgalNamed on SEC filing
Board
SP
S. P. KothariBoard director
BT

Bharat TewarieBoard director
PD

Peter DolanBoard director
DP

David PageBoard director
Reported raises · per SEC filings
Form D private placements$6.2M disclosed across 3 rounds · 2018–2024
▶$4.5MraisedMar 2025 · 36 investors · PharmaceuticalsRule 506(b)
▶$4.5MraisedMar 2025 · 36 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- S. P. KothariDirector
- Parag MehtaExecutive Officer, Director
- Bharat TewarieDirector
- Peter DolanDirector
- David PageDirector
- Offering amount
- $8M
- Amount sold
- $4.5M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$600KraisedFeb 2022 · 13 investors · BiotechnologyRule 506(b)
▶$600KraisedFeb 2022 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Parag MehtaExecutive Officer, Director
- Guha BalaDirector
- Bharat TewarieDirector
- Offering amount
- $5M
- Amount sold
- $600K
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedMar 2018 · 4 investors · BiotechnologyRule 506(b)
▶$1.1MraisedMar 2018 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sharmila MudgalExecutive Officer, Director
- Parag MehtaExecutive Officer, Director
- SP KothariDirector
- Offering amount
- $2.5M
- Amount sold
- $1.1M
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
DoximityDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.
Companies working in the same space as Aveta Biomics.
Frequently asked questions
- What does Aveta Biomics do?
- Aveta Biomics develops cancer therapeutics based on Orthologous Molecular Structures (OMS), metabolites from organisms with orthologous genes and processes, combined using an evolutionary-biology-based platform. Its drugs aim to treat and prevent cancers while addressing tumor heterogeneity and drug resistance.
- How much funding has Aveta Biomics raised?
- Aveta Biomics has disclosed $6.2M raised across 3 rounds.
- Where is Aveta Biomics headquartered?
- Aveta Biomics is headquartered in Bedford, US.
